• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Transphorm Announces Fiscal 2023 Fourth Quarter and Year End Financial Results and Provides Business Update

    6/27/23 4:30:00 PM ET
    $TGAN
    Semiconductors
    Technology
    Get the next $TGAN alert in real time by email

    Company to Initiate a Review of Strategic Opportunities to Enhance Shareholder Value in Fiscal Q2

    Fiscal Year 2023 Product Revenue up 21% Year-Over-Year

    Company to Host Webcast Today at 5:00 p.m. ET to Review Financials and Provide a Business Update

    Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today financial results for the fiscal fourth quarter and year ended March 31, 2023.

    Fiscal 2023 and Fourth Quarter and Recent Highlights

    Corporate Updates

    • Raised $9.3 million through the exercise of existing warrants and a private placement of common stock.
    • Fully repaid $12.0 million Nexperia loan in April, ended exclusivity for Nexperia in the four-wheeler Electric Vehicle segment.
    • Announced rights offering for up to $15 million of common stock, in which certain key stockholders have indicated their interest in participating.
    • Appointed Dr. Primit Parikh and Dr. Umesh Mishra as President and Chief Executive Officer of the Company, and Chair of the Board of Directors, respectively.

    Key Business Highlights

    • Reported revenue of $3.2 million for the fourth quarter of fiscal 2023, which was primarily impacted by a government contract delay, the revenue from which will be recognized commencing in the first quarter of fiscal 2024. Product revenue for the fourth quarter of fiscal 2023 was at the Company's targeted $3.2 million.
    • Fiscal 2023 product revenue increased to $14.7 million, a 21% increase year-over-year.
    • Strong 5-year pipeline opportunity now stands at over $440 million, up 7% from the Company's previous update in February 2023.
    • Increased design-ins and opportunities nearing or in production are currently expected to result in sequential product revenue growth resuming in the second quarter of fiscal 2024.
    • Secured a contract for up to $15 million from the National Security Technology Accelerator (NSTXL), to manufacture advanced GaN epiwafers under the ECLIPSE Project.

    High Power Segment Update – Transphorm a Worldwide Leader in GaN

    • Increased total design-ins for higher power (300 Watt – 4 Kilowatt) to over 60 (with 30 in production), an increase of 25% from the Company's previous update in February 2023.
    • Only GaN company with a proven ramp in the microinverter segment, with several hundred thousand devices in the field (800W, 1500W inverters) and targeted ramp to over $1 million annual revenue over the next 12 months with the Company's largest customer. Other key design-ins ongoing.
    • Announced a low-cost driver solution for SuperGaN FETs, strengthening the Company's value proposition in segments such as LED lighting, charging, microinverters, UPS and gaming computers.
    • Launched the first 1200 V FET simulation model and preliminary datasheet, a 1200V GaN-on-Sapphire power semiconductor backing the Company's ability to support future automotive power systems and compete with 1200V SiC devices.
    • Launched the Company's third, high-power GaN design tool using a digital signal controller from Microchip Technology, featuring a 3.0 kW DC-to-AC non-isolated full-bridge inverter evaluation board.

    Low Power Segment Update – Transphorm enables superior performance

    • Increased total design-ins for power adapters and fast chargers (< 300 W) to over 90 (with over 25 in production), an increase of 10% from the Company's previous update in February 2023.
    • Weltrend Semiconductor Inc., the global leader in adapter USB Power Delivery (PD) Controller Integrated Circuits (ICs) released an integrated GaN System-in-Package (SiP) for 65 W fast charging applications, in collaboration with us, utilizing our high-performance, high-reliability GaN chips.
    • In a recent tear-down study of the 280 W Razer gaming power supply1, Transphorm's drop-in SuperGaN out-performed different e-mode devices (including Leading foundry-made GaN) with a device temperature reduction of between 20% - 50%, higher efficiency, and expected reliability.
    • Announced six surface mount devices available in Industry Standard PQFN 5x6 and 8x8 packages (for both low and high-power segments).

    "We continue to see strong fundamental growth trends driven primarily by increased design wins for both the high-power and low-power market segments. We believe these trends point to the Company resuming sequential product revenue growth beginning in the second quarter of fiscal 2024," commented Transphorm's President, CEO and Co-Founder, Primit Parikh. "Our differentiated GaN semiconductors lead the industry in performance and reliability, carrying the only reported broad power spectrum reliability ratings for GaN power and over 175 billion hours in the field. Our increased design-ins, the end customer momentum in ramping GaN, and the recent broad market excitement in GaN power is driving our desire to commence a strategic review of various opportunities to enhance shareholder value."

    "We believe the past quarter and fiscal year have been extremely important toward positioning us strategically for future growth. We expect our recently announced rights offering and the asset-based debt financing initiatives we are pursuing will significantly improve our cash position and put us in a strong position to pursue the increased opportunity funnel and allow us to focus on product innovation, operational capabilities and collaborative opportunities," stated Cameron McAulay, Chief Financial Officer.

    1 Cascode GaN improves efficiency – A teardown of Razer 280W Power Adapter - Power Electronics News

    Fiscal 2023 Fourth Quarter Financial Results

    Revenue for the fourth quarter of fiscal 2023 was $3.2 million, compared to $4.5 million in the prior quarter and $4.9 million for the fourth quarter of fiscal 2022.

    Operating expenses on a GAAP basis were $8.5 million in the fourth quarter of fiscal 2023, compared to $7.2 million in the prior quarter and $5.6 million in the fourth quarter of fiscal 2022. Operating expenses for the fourth quarter of fiscal 2023 consisted of R&D expenses of $3.0 million and SG&A expenses of $5.5 million. On a non-GAAP basis, operating expenses in the fourth quarter of fiscal 2023 were $7.5 million, compared with non-GAAP operating expenses of $6.0 million in the prior quarter and $4.7 million in the fourth quarter of fiscal 2022.

    GAAP net loss for the fourth quarter of fiscal 2023 was ($8.8) million, or ($0.15) per share, compared to GAAP net loss of ($10.5) million, or ($0.18) per share, in the prior quarter, and GAAP net loss of ($5.0) million, or ($0.09) per share, in the fourth quarter of fiscal 2022. On a non-GAAP basis, net loss for the fourth quarter of fiscal 2023 was ($7.2) million, or ($0.13) per share, compared to non-GAAP net loss of ($8.5) million, or ($0.15) per share, in the prior quarter, and non-GAAP net loss of ($3.5) million, or ($0.07) per share, in the fourth quarter of fiscal 2022.

    Fiscal 2023 Full Year Financial Results

    Revenue for the fiscal 2023 was $16.5 million, compared to $24.1 million for fiscal 2022, due primarily to an $8.0 million decrease in licensing revenue. For fiscal 2023, product sales were $14.7 million, an increase of 21% compared to fiscal 2022.

    Operating expenses on a GAAP basis were $27.8 million in fiscal 2023, compared to $21.4 million in fiscal 2022. Operating expenses for the fiscal 2023 consisted of R&D expenses of $8.9 million and SG&A expenses of $18.9 million. On a non-GAAP basis, operating expenses in fiscal 2023 were $24.2 million, compared with non-GAAP operating expenses of $18.3 million in fiscal 2022.

    GAAP net loss for fiscal 2023 was ($30.6) million, or ($0.54) per share, compared to GAAP net loss of ($10.2) million, or ($0.22) per share, in fiscal 2022. On a non-GAAP basis, net loss for fiscal 2023 was ($24.6) million, or ($0.44) per share, compared to non-GAAP net loss of ($6.4) million, or ($0.14) per share, in fiscal 2022.

    Cash, cash equivalents and restricted cash as of March 31, 2023, were $16.0 million. The increased quarterly burn was driven by lower revenue, due to the delay in securing the new government contract with NSTXL and increased Days Sales Outstanding (DSO). During the first quarter of fiscal 2024, we were awarded the NSTXL contract, resulting in revenue being recognized commencing in such quarter, and DSOs improved to historical levels.

    Fiscal 2024 First Quarter Guidance

    For the first quarter of fiscal 2024, the Company expects:

    • Revenue in the range of $5.8 million to $6.2 million;
    • GAAP gross margins in the 30-34% range; and
    • GAAP net loss per share in the $(0.10) to $(0.13) range.

    The Company currently forecasts it will have cash runway into the second half of September 2023, not including the rights offering, asset-based debt or any other financings. If the rights offering is fully subscribed and the Company completes the asset-based debt financing that it is pursuing, the Company would have cash runway well into fiscal 2025. Please refer to the Company's Annual Report on Form 10-K for additional information and liquidity disclosures.

    Conference Call and Webcast Information

    Event:

    Transphorm Fiscal 2023 Fourth Quarter and Full Year Financial Results

    Date:

    Tuesday, June 27, 2023

    Time:

    5:00 p.m. Eastern Time

    Registration:

    https://register.vevent.com/register/BIff2d46a2f63c464b80cc25344b9c6e09

    Investors and analysts may also join the webcast on the Events section on the Company's website.

    A replay and the supporting presentation materials will be available on the day of the conference call and for approximately 90 days on the Investor Relations section of the Company's website.

    About Transphorm

    Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry's first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company's vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm's innovations are moving power electronics beyond the limitations of silicon to achieve over 99% efficiency, 40% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa and WeChat @ Transphorm GaN.

    Non-GAAP Financial Measures

    This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

    Transphorm believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Transphorm believes that these non-GAAP financial measures provide additional insight into Transphorm's ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Transphorm's results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation, amortization, change in fair value of promissory note and other income in joint venture.

    A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company's expectations related to its planned rights offering and the asset-based debt financing initiatives it is pursuing, including the potential proceeds from such efforts; the Company's current expectation regarding its cash runway, without any additional financing; the expected date through which proceeds from the rights offering and any debt financing, if consummated, would fund the Company's operations; the expectation that the rights offering and debt financing initiatives will allow the Company to increase its focus on product innovation, operational capabilities and collaborative opportunities; expected key stockholder participation in the rights offering; the Company's intent to conduct a strategic review in the second quarter of fiscal 2024; the Company's 5-year pipeline and anticipated future growth; the Company's expectation that sequential product revenue growth will resume in the second quarter of fiscal 2024; the Company's targeted ramp in the microinverter segment; the Company's expectations for future products, design-ins and market acceptance; the Company's guidance for the first quarter of fiscal 2024; and the information set forth in the quotes by the Company's management set forth herein. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: prevailing market conditions; the Company's ability to commence and successfully complete the rights offering as expected; whether the Company's stockholders of record (including those that have indicated interest in participating in the rights offering) will exercise their rights to purchase common stock and the amount subscribed; whether the Company will be able to successfully close any debt financing; that any funds raised through the rights offering or any debt financing may not fund the Company's working capital requirements for as long as anticipated; that the Company's current forecasted cash runway, without any additional financing, may not last as long as anticipated; that the Company's anticipated strategic review may not result in any transaction (or that the terms of such transaction may not be favorable or acceptable to the Company or its stockholders); risks related to Transphorm's operations, such as additional financing requirements, access to capital and market acceptance of its current and future products; competition; the ability of Transphorm to protect its intellectual property rights; and other risks set forth in the Company's filings with the Securities and Exchange Commission, including under the caption "Risk Factors" and elsewhere therein. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

    Transphorm, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands)

     

     

    March 31, 2023

    (unaudited)

     

    March 31, 2022

    (audited)

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    15,527

     

     

    $

    33,435

     

    Restricted cash

     

    500

     

     

     

    500

     

    Accounts receivable

     

    4,396

     

     

     

    2,558

     

    Inventory

     

    8,406

     

     

     

    6,330

     

    Prepaid expenses and other current assets

     

    1,859

     

     

     

    1,971

     

    Total current assets

     

    30,688

     

     

     

    44,794

     

    Property and equipment, net

     

    7,890

     

     

     

    1,649

     

    Operating lease right-of-use assets

     

    3,033

     

     

     

    —

     

    Goodwill

     

    1,079

     

     

     

    1,180

     

    Intangible assets, net

     

    321

     

     

     

    617

     

    Investment in joint venture

     

    715

     

     

     

    143

     

    Other assets

     

    726

     

     

     

    263

     

    Total assets

    $

    44,452

     

     

    $

    48,646

     

     

     

     

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable and accrued expenses

    $

    7,895

     

     

    $

    3,588

     

    Deferred revenue

     

    —

     

     

     

    346

     

    Accrued interest

     

    180

     

     

     

    180

     

    Accrued payroll and benefits

     

    1,458

     

     

     

    1,171

     

    Operating lease liabilities

     

    404

     

     

     

    —

     

    Revolving credit facility

     

    12,000

     

     

     

    —

     

    Total current liabilities

     

    21,937

     

     

     

    5,285

     

    Revolving credit facility, net of current portion

     

    —

     

     

     

    12,000

     

    Operating lease liabilities, net of current portion

     

    2,670

     

     

     

    —

     

    Other liabilities

     

    230

     

     

     

    —

     

    Total liabilities

     

    24,837

     

     

     

    17,285

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock

     

    6

     

     

     

    5

     

    Additional paid-in capital

     

    230,272

     

     

     

    211,190

     

    Accumulated deficit

     

    (209,236

    )

     

     

    (178,638

    )

    Accumulated other comprehensive loss

     

    (1,427

    )

     

     

    (1,196

    )

    Total Stockholders' equity

     

    19,615

     

     

     

    31,361

     

    Total liabilities and stockholders' equity

    $

    44,452

     

     

    $

    48,646

     

    Transphorm, Inc.

    Condensed Consolidated Statements of Operations (unaudited)

    (in thousands except share and per share data)

     

     

    Three Months Ended

     

    Twelve Months Ended

     

    March 31, 2023

     

    December 31, 2022

     

    March 31, 2022

     

    March 31, 2023

     

    March 31, 2022

    Revenue, net

    $

    3,192

     

     

    $

    4,493

     

     

    $

    4,927

     

     

    $

    16,511

     

     

    $

    24,050

     

    Cost of goods sold

     

    3,017

     

     

     

    7,162

     

     

     

    3,789

     

     

     

    17,461

     

     

     

    12,530

     

    Gross (loss) profit

     

    175

     

     

     

    (2,669

    )

     

     

    1,138

     

     

     

    (950

    )

     

     

    11,520

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

    Research and development

     

    3,013

     

     

     

    2,325

     

     

     

    1,632

     

     

     

    8,908

     

     

     

    6,655

     

    Sales and marketing

     

    1,651

     

     

     

    1,447

     

     

     

    1,047

     

     

     

    5,247

     

     

     

    3,535

     

    General and administrative

     

    3,854

     

     

     

    3,457

     

     

     

    2,917

     

     

     

    13,672

     

     

     

    11,226

     

    Total operating expenses

     

    8,518

     

     

     

    7,229

     

     

     

    5,596

     

     

     

    27,827

     

     

     

    21,416

     

    Loss from operations

     

    (8,343

    )

     

     

    (9,898

    )

     

     

    (4,458

    )

     

     

    (28,777

    )

     

     

    (9,896

    )

    Interest expense

     

    180

     

     

     

    184

     

     

     

    181

     

     

     

    730

     

     

     

    792

     

    Loss in joint venture

     

    659

     

     

     

    799

     

     

     

    677

     

     

     

    2,724

     

     

     

    3,971

     

    Changes in fair value of promissory note

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (605

    )

    Other income, net

     

    (392

    )

     

     

    (421

    )

     

     

    (317

    )

     

     

    (1,633

    )

     

     

    (3,819

    )

    Loss before tax expense

     

    (8,790

    )

     

     

    (10,460

    )

     

     

    (4,999

    )

     

     

    (30,598

    )

     

     

    (10,235

    )

    Tax expense

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Net loss

    $

    (8,790

    )

     

    $

    (10,460

    )

     

    $

    (4,999

    )

     

    $

    (30,598

    )

     

    $

    (10,235

    )

    Net loss per share - basic and diluted

    $

    (0.15

    )

     

    $

    (0.18

    )

     

    $

    (0.09

    )

     

    $

    (0.54

    )

     

    $

    (0.22

    )

    Weighted average common shares outstanding - basic and diluted

     

    57,144,218

     

     

     

    56,739,450

     

     

     

    53,343,862

     

     

     

    56,227,007

     

     

     

    46,056,331

     

    Transphorm, Inc.

    Reconciliation of GAAP and Non-GAAP Financial Information (unaudited)

    (in thousands except per share data)

     

     

    Three Months Ended

     

    Twelve Months Ended

     

    March 31, 2023

     

    December 31, 2022

     

    March 31, 2022

     

    March 31, 2023

     

    March 31, 2022

     

    GAAP net loss

    $

    (8,790

    )

     

    $

    (10,460

    )

     

    $

    (4,999

    )

     

    $

    (30,598

    )

     

    $

    (10,235

    )

     

    Adjustments:

     

     

     

     

     

     

     

     

     

     

    Stock-based compensation

     

    858

     

     

     

    1,123

     

     

     

    758

     

     

     

    3,199

     

     

     

    2,614

     

     

    Depreciation

     

    174

     

     

     

    180

     

     

     

    147

     

     

     

    672

     

     

     

    547

     

     

    Amortization

     

    74

     

     

     

    74

     

     

     

    74

     

     

     

    296

     

     

     

    296

     

     

    Total other expense, net

     

    447

     

     

     

    562

     

     

     

    541

     

     

     

    1,821

     

     

     

    339

     

     

    Total adjustments to GAAP net loss

     

    1,553

     

     

     

    1,939

     

     

     

    1,520

     

     

     

    5,988

     

     

     

    3,796

     

     

    Non-GAAP net loss

    $

    (7,237

    )

     

    $

    (8,521

    )

     

    $

    (3,479

    )

     

    $

    (24,610

    )

     

    $

    (6,439

    )

     

    GAAP net loss per share - basic and diluted

    $

    (0.15

    )

     

    $

    (0.18

    )

     

    $

    (0.09

    )

     

    $

    (0.54

    )

     

    $

    (0.22

    )

     

    Adjustment

     

    0.02

     

     

     

    0.03

     

     

     

    0.02

     

     

     

    0.10

     

     

     

    0.08

     

     

    Non-GAAP net loss per share - basic and diluted

    $

    (0.13

    )

     

    $

    (0.15

    )

     

    $

    (0.07

    )

     

    $

    (0.44

    )

     

    $

    (0.14

    )

     

    Weighted average common shares outstanding - basic and diluted

     

    57,144,218

     

     

     

    56,739,450

     

     

     

    53,343,862

     

     

     

    56,227,007

     

     

     

    46,056,331

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

    March 31, 2023

     

    December 31, 2022

     

    March 31, 2022

     

    March 31, 2023

     

    March 31, 2022

    GAAP operating expenses

    $

    8,518

     

    $

    7,229

     

    $

    5,596

     

    $

    27,827

     

    $

    21,416

    Adjustments:

     

     

     

     

     

     

     

     

     

    Stock-based compensation

     

    796

     

     

    1,035

     

     

    715

     

     

    2,955

     

     

    2,453

    Depreciation

     

    101

     

     

    102

     

     

    94

     

     

    394

     

     

    385

    Amortization

     

    74

     

     

    74

     

     

    74

     

     

    296

     

     

    296

    Total adjustments to GAAP operating expenses

     

    971

     

     

    1,211

     

     

    883

     

     

    3,645

     

     

    3,134

    Non-GAAP operating expenses

    $

    7,547

     

    $

    6,018

     

    $

    4,713

     

    $

    24,182

     

    $

    18,282

    Transphorm, Inc.

    Condensed Consolidated Statements of Cash Flows (unaudited), (in thousands)

     

     

     

    Twelve Months Ended March 31,

     

    2023

     

    2022

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (30,598

    )

     

    $

    (10,235

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Provision for inventory

     

    3,127

     

     

     

    196

     

    Depreciation and amortization

     

    968

     

     

     

    843

     

    Amortization of right-of-use assets

     

    566

     

     

     

    —

     

    Perpetual licensing revenue from a related party

     

    —

     

     

     

    (8,000

    )

    Stock-based compensation

     

    3,199

     

     

     

    2,614

     

    Interest cost

     

    —

     

     

     

    107

     

    Gain on promissory note conversion

     

    —

     

     

     

    (1,222

    )

    Gain on sale of equipment

     

    (106

    )

     

     

    —

     

    Loss in joint venture

     

    2,724

     

     

     

    2,516

     

    Changes in fair value of derivative instruments

     

    (14

    )

     

     

    —

     

    Changes in fair value of promissory note

     

    —

     

     

     

    (605

    )

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (1,838

    )

     

     

    (940

    )

    Inventory

     

    (5,203

    )

     

     

    (4,303

    )

    Prepaid expenses and other current assets

     

    125

     

     

     

    (518

    )

    Other assets

     

    (463

    )

     

     

    11

     

    Accounts payable, accrued expenses, and other liabilities

     

    1,586

     

     

     

    198

     

    Deferred revenue

     

    (346

    )

     

     

    (159

    )

    Accrued payroll and benefits

     

    288

     

     

     

    (239

    )

    Operating lease liabilities

     

    (524

    )

     

     

    —

     

    Net cash used in operating activities

     

    (26,509

    )

     

     

    (19,736

    )

    Cash flows from investing activities:

     

     

     

    Purchases of property and equipment

     

    (6,936

    )

     

     

    (595

    )

    Proceeds from sale of equipment

     

    111

     

     

     

    —

     

    Investment in joint venture

     

    (3,321

    )

     

     

    (4,526

    )

    Net cash used in investing activities

     

    (10,146

    )

     

     

    (5,121

    )

    Cash flows from financing activities:

     

     

     

    Proceeds from stock option exercise

     

    710

     

     

     

    221

     

    Proceeds from issuance of common stock

     

    16,000

     

     

     

    50,900

     

    Cost associated with issuance of common stock

     

    (280

    )

     

     

    (1,127

    )

    Payment for taxes related to net share settlement of restricted stock units

     

    (546

    )

     

     

    (768

    )

    Proceeds from exercise of warrants

     

    2,950

     

     

     

    272

     

    Net cash provided by financing activities

     

    18,834

     

     

     

    49,498

     

    Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

     

    (87

    )

     

     

    (206

    )

    Net (decrease) increase in cash, cash equivalents and restricted cash

     

    (17,908

    )

     

     

    24,435

     

    Cash, cash equivalents and restricted cash at beginning of period

     

    33,935

     

     

     

    9,500

     

    Cash, cash equivalents and restricted cash at end of period

    $

    16,027

     

     

    $

    33,935

     

    Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets

     

     

     

    Cash and cash equivalents

    $

    15,527

     

     

    $

    33,435

     

    Restricted cash

     

    500

     

     

     

    500

     

    Cash, cash equivalents and restricted cash at end of period

    $

    16,027

     

     

    $

    33,935

     

     

     

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230627964440/en/

    Get the next $TGAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TGAN

    DatePrice TargetRatingAnalyst
    6/15/2022$9.00 → $6.50Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $TGAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Transphorm downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Transphorm from Buy to Neutral and set a new price target of $6.50 from $9.00 previously

    6/15/22 7:40:43 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Phorm Investors L.P. sold $124,501,037 worth of shares (24,411,968 units at $5.10) (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:30:24 PM ET
    $TGAN
    Semiconductors
    Technology

    PRESIDENT AND CEO Parikh Primit returned 489,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:22 PM ET
    $TGAN
    Semiconductors
    Technology

    Chief Financial Officer Mcaulay Cameron returned 182,048 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:17 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Efinix Appoints Cameron McAulay as Chief Financial Officer

    McAulay Brings a Decade of Public-Company Semiconductor CFO Experience to Support Efinix's Global Expansion Efinix, Inc., the FPGA pioneer accelerating edge AI innovation, today announced the appointment of Cameron McAulay as Chief Financial Officer and Senior Vice President Finance. McAulay brings more than 20 years of financial leadership experience in the semiconductor and technology industries, including over a decade of service as CFO at publicly traded companies, making him uniquely qualified to help guide Efinix through its next stage of growth and value creation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303081

    3/3/26 11:00:00 AM ET
    $IVAC
    $TGAN
    Industrial Machinery/Components
    Technology
    Semiconductors

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Demonstrates a Bidirectional SuperGaN Power Supply with New Reference Design for E-Mobility and Energy/Industrial Markets

    300 W DC-to-DC Battery Charger Board Showcases Key Capability of GaN Technology Necessary to Advance E-Mobility Applications Transphorm, Inc. (NASDAQ:TGAN), the global leader in robust GaN power semiconductors, today announced the release of a new 300 W DC-to-DC GaN reference design for 2- and 3-wheeled electric vehicle battery chargers. The TDDCDC-TPH-IN-BI-LLC-300W-RD design uses TP65H150G4PS 150 mOhm SuperGaN® FETs in a robust TO-220 package to power a high performing, high efficiency energy harvesting and distribution battery charging system. The new board notably demonstrates one of the most anticipated value propositions of a GaN power supply: bidirectionality. This capability indic

    6/11/24 3:00:00 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    SEC Filings

    View All

    SEC Form 15-12G filed by Transphorm Inc.

    15-12G - Transphorm, Inc. (0001715768) (Filer)

    7/1/24 9:01:49 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:13 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:04 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Transphorm Inc.

    SC 13D/A - Transphorm, Inc. (0001715768) (Subject)

    6/20/24 4:30:51 PM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/14/24 10:15:50 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/13/24 1:41:50 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Leadership Updates

    Live Leadership Updates

    View All

    Efinix Appoints Cameron McAulay as Chief Financial Officer

    McAulay Brings a Decade of Public-Company Semiconductor CFO Experience to Support Efinix's Global Expansion Efinix, Inc., the FPGA pioneer accelerating edge AI innovation, today announced the appointment of Cameron McAulay as Chief Financial Officer and Senior Vice President Finance. McAulay brings more than 20 years of financial leadership experience in the semiconductor and technology industries, including over a decade of service as CFO at publicly traded companies, making him uniquely qualified to help guide Efinix through its next stage of growth and value creation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303081

    3/3/26 11:00:00 AM ET
    $IVAC
    $TGAN
    Industrial Machinery/Components
    Technology
    Semiconductors

    Transphorm Announces Appointment of Company Co-founders as Chief Executive Officer and Board Chair

    Follows Retirement of CEO and as part of the Company's Planned Succession Strategy Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced that its Board of Directors has appointed Dr. Primit Parikh as President and Chief Executive Officer of the Company and as a member of the Board. The Board also appointed Dr. Umesh Mishra to serve as Chair of the Board. Both of these appointments are effective May 15, 2023. Dr. Parikh and Dr. Mishra, who co-founded the Company's main operating subsidiary Transphorm Technology Inc., succeed Mario Rivas, who has served as the Company's Chief Executi

    5/15/23 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Appoints Six Company Leaders

    Company Veterans and Industry Leaders to Drive Next Phase of Growth Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and a global supplier of high reliability, high performance gallium nitride (GaN) power conversion products—announced today the appointment of six company leaders. The roles are being filled by company veterans as well as newly hired experts, strategically building out Transphorm's executive bench. The collective sales, operations, engineering, and product marketing skillsets brought by these individuals will contribute to Transphorm's business growth and customer support strategies as the company responds to a rapidly rising demand for high voltage GaN power semiconductors acros

    10/27/22 9:00:00 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Financials

    Live finance-specific insights

    View All

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Third Quarter Results and Provides Business Update

    Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the third quarter of its fiscal year ending March 31, 2024 ("Q3 Fiscal 2024"). On January 10, 2024, Transphorm announced that it entered into a definitive agreement to be acquired by a subsidiary of Renesas Electronics Corporation. The transaction values Transphorm at approximately $339 million. Key Business Highlights Reported total revenue of $4.7 million for Q3 Fiscal 2024, an increase of 4.0% over the same quarter last year and a decrease of 6.8% from the prior quarter. Product revenue was $3.2 million in the quarter, a decrease of 20%

    2/20/24 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Second Quarter Results and Provides Business Update

    - Reports Second Quarter Year-Over-Year Revenue Grew 37% to $5.0 Million as Gross Margin Increased by 11.5% to 23% - Product Revenue Increased to $3.55 Million, Up 18% Over the Prior Quarter - Recently Engaged BofA Securities, Inc. to Act as Financial Advisor in Company's Strategic Review to Enhance Stockholder Value - Company to Host Webcast Today at 5:00 p.m. EST to Review Quarterly Results and Provide a Business Update Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the second quarter of its fiscal year ending March 31, 2024 ("Q2 Fiscal 2024"). Primit Parikh, Transphorm's CEO and Co-Fo

    11/9/23 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology